Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align with the label regarding indications, dosing context, and key safety warnings, but include multiple statements beyond the label (eg, patent/generic market commentary, broader market claims) and omit explicit contraindication details. Overall, partial alignment.
Category Scores
Accurate Statements
Esmolol hydrochloride is indicated for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate is desirable.
1
Esmolol hydrochloride is indicated for rapid control of ventricular rate in atrial fibrillation.
1
Esmolol hydrochloride is indicated for rapid control of ventricular rate in atrial flutter.
1
Esmolol hydrochloride is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period.
1
Esmolol hydrochloride is employed to manage high blood pressure in the immediate post-operative period.
1
Esmolol hydrochloride carries risks, including hypotension (low blood pressure).
1
Esmolol hydrochloride carries risks, including bradycardia (slow heart rate).
1
Esmolol hydrochloride carries risks, including heart failure exacerbation.
1
In rare cases, it can cause bronchospasm, particularly in patients with a history of asthma or other obstructive airway diseases.
1
Careful monitoring of vital signs and patient response is crucial during administration.
1
Calcium channel antagonists are among the listed drug interactions with esmolol hydrochloride.
1
The choice of treatment depends on the patient's underlying condition, other medical issues, and desired pharmacological profile.
1
Unsupported Statements
Esmolol hydrochloride is an ultra-short-acting beta-blocker.
Label indicates short-term use and rapid rate control but does not use the descriptor 'ultra-short-acting'.
Its rapid onset and short duration of action make it valuable in acute care.
Label does not explicitly state 'rapid onset' or 'acute care'; describes short-term use and dosing, including up to 48 hours.
Patent protection for esmolol hydrochloride has largely expired, allowing for the development and marketing of generic versions.
Patent status is not discussed in the label.
DrugPatentWatch.com tracks patent expirations for numerous drugs, including esmolol hydrochloride, providing data on when market exclusivity is expected to end or has ended for various formulations and geographical regions.
Not discussed in the label.
The market landscape has consequently shifted towards generic competition.
Not discussed in the label.
With patent expiries, the manufacturing of esmolol hydrochloride has become more diffused.
Not discussed in the label.
Several pharmaceutical companies now produce generic versions of the drug.
Not discussed in the label.
Original brand names may still exist, but generic manufacturers play a significant role in market supply and pricing.
Not discussed in the label.
The introduction of generic esmolol hydrochloride has generally led to a decrease in overall market pricing.
Not discussed in the label.
Generic manufacturers compete with each other and with the originator product, driving down costs for healthcare providers and potentially increasing accessibility.
Not discussed in the label.
Pricing can vary based on manufacturer, dosage form, and geographical region.
Not discussed in the label.
Other medications are available for managing rapid heart rates and hypertension, depending on the specific clinical scenario.
Not stated as a general claim in the label.
These can include other beta-blockers with longer durations of action.
Not explicitly listed in the label.
These can include antiarrhythmic drugs.
Not explicitly listed as a category within the label; interactions focus on specific agents.
Contradictions
Important Omissions
Pregnancy risk information (label section 8.1) not addressed in claims.
Importance:
High
Pediatric safety information (label sections such as 8.4) not addressed in claims.
Importance:
High
Explicit contraindications for esmolol use are not described in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Many risks (hypotension, bradycardia, heart failure, bronchospasm) are acknowledged with monitoring recommendations; overall risk described as dose-related and manageable with appropriate monitoring.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Limit claims to label-supported indications, dosing, and safety; remove or clearly label non-label content (eg, patent/generic market commentary) and add explicit contraindication details if evaluating against the label.